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Brief Definit ive Report
Age-related aggregation of amyloid- (A) is 
an upstream pathological event in Alzheimer’s 
disease (AD) pathogenesis (Holtzman et al., 2011; 
Sperling et al., 2011). As the accumulation and 
aggregation of A in the brain is known to de-
velop 10–15 yr before the initial symptoms 
of AD, understanding the factors that lead to 
A aggregation are likely to be important in de-
laying the onset of this pathology and delaying/
preventing AD (Holtzman et al., 2011; Sperling 
et al., 2011). Diverse lines of in vitro and in vivo 
studies have shown that synaptic activity and 
specifically synaptic vesicle release is coupled with 
presynaptic A release (Kamenetz et al., 2003; 
Cirrito et al., 2008; Bero et al., 2011; Roh et al., 
2012). In addition, sleep plays a role in the reg-
ulation of synaptic weight in the brain such that 
sleep appears to downscale the slow wave ac-
tivity of the brain caused by accumulated load 
of synaptic potentiation during wakefulness 
(Vyazovskiy et al., 2009). Poor sleep quality and 
insufficient amounts of sleep have been noted 
in humans with preclinical evidence of AD (Roh 
et al., 2012; Ju and Holtzman, 2013; Ju et al., 
2014). These observations suggest that under-
standing how integrated synaptic and network 
activity as measured by the sleep–wake cycle 
regulates A may provide novel insights into 
AD pathogenesis. However, how the amount 
and quality of sleep affect A aggregation is not 
yet well understood (Ju et al., 2014). Orexins 
(hypocretins) initiate and maintain wakefulness, 
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Age-related aggregation of amyloid- (A) is an upstream pathological event in Alzheimer’s 
disease (AD) pathogenesis, and it disrupts the sleep–wake cycle. The amount of sleep 
declines with aging and to a greater extent in AD. Poor sleep quality and insufficient 
amounts of sleep have been noted in humans with preclinical evidence of AD. However, 
how the amount and quality of sleep affects A aggregation is not yet well understood. 
Orexins (hypocretins) initiate and maintain wakefulness, and loss of orexin-producing 
neurons causes narcolepsy. We tried to determine whether orexin release or secondary 
changes in sleep via orexin modulation affect A pathology. Amyloid precursor protein (APP)/
Presenilin 1 (PS1) transgenic mice, in which the orexin gene is knocked out, showed a 
marked decrease in the amount of A pathology in the brain with an increase in sleep 
time. Focal overexpression of orexin in the hippocampus in APP/PS1 mice did not alter the 
total amount of sleep/wakefulness and the amount of A pathology. In contrast, sleep 
deprivation or increasing wakefulness by rescue of orexinergic neurons in APP/PS1 mice 
lacking orexin increased the amount of A pathology in the brain. Collectively, modulation 
of orexin and its effects on sleep appear to modulate A pathology in the brain.
© 2014 Roh et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
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Figure 1. Marked reduction of A pathology in the APP/PS1/OR/ mice compared with APP/PS1 mice. (A–I) The amount of A pathology 
was noted at 3.5 (A–C) and 8.5 mo (D–F) in APP/PS1-21 mouse line and at 6 mo in APP/PS1E9 mouse line (G–I). (J and K) Amount of wakefulness at 
3 mo of age before the onset of A pathology in the brain was compared between APP/PS1E9 and APP/PS1E9/OR/ mice. Each mouse was inves-
tigated independently one time. Data are presented as mean ± SEM (n = 4–12 in each group, two-tailed Student’s t test in C, F, and I and Mann-Whitney 
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RESULTS AND DISCUSSION
Marked reduction of A pathology in the  
APP/Presenilin 1 (PS1)/Orexin knockout (OR/) mice
To more specifically address the role of orexin in regulating 
A levels and pathology, we used APP/PS1-21 transgenic mice 
(Radde et al., 2006), which begin to develop A deposition 
at 2 mo of age, and bred them to OR/ mice (de Lecea 
et al., 1998; Chemelli et al., 1999). When orexin was knocked 
out in APP/PS1-21 mice (APP/PS1-21/OR/ mice), there 
was a marked reduction of A plaque pathology at 3.5 mo as 
well as at 8.5 mo of age compared with APP/PS1-21 mice 
(Fig. 1, A–F). Similar patterns of reduction in A deposition 
were also seen when orexin was knocked out in another 
mouse model that develops A deposition, APP/PS1E9 mice 
( Jankowsky et al., 2004), which begin to develop A deposition 
at 4 mo of age. APP/PS1E9/OR/ mice had a marked re-
duction in A deposition at 6 mo of age compared with APP/ 
PS1E9 mice expressing orexin (Fig. 1, G–I). APP/PS1E9/
OR/ mice demonstrated significantly decreased wakefulness 
and loss of orexin-producing neurons causes narcolepsy 
(de Lecea et al., 1998; Chemelli et al., 1999).
Levels of soluble A in the extracellular interstitial fluid 
(ISF) of the hippocampus in mice are dynamically and posi-
tively associated with minutes awake per hour and negatively 
associated with time asleep (Kang et al., 2009). In addition, 
the sleep–wake cycle also affects the A pathology in the brain. 
A study in mice showed that intracerebral administration of 
orexin can acutely increase both wakefulness and A levels 
and systemic treatment with an orexin receptor antagonist 
decreased A deposition in amyloid precursor protein (APP) 
transgenic mouse models (Kang et al., 2009). Pharmacologi-
cal experiments suggest that orexin and the sleep–wake cycle 
appear to be related to regulation of A levels. We sought to 
determine for the first time whether genetic manipulation of 
orexin has similar effects as pharmacological manipulation and, 
importantly, whether orexin is influencing A levels and A 
pathology directly via orexin signaling or indirectly via its ef-
fects on the sleep–wake cycle.
Figure 2. Marked reduction of amyloid pathology in the APP/PS1/OR/ mice compared with APP/PS1 mice. (A–L) Amyloid pathology mea-
sured by A immunoreactivity and number of amyloid plaques after X-34 staining is noted at 3.5 (A, B, G, and H) and 8.5 mo (C, D, I, and J) in the APP/
PS1-21 mouse line and at 6 mo in the APP/PS1E9 mouse line (E, F, K, and L). Each mouse was investigated independently one time. Data are presented as 
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instituted in 1.5-mo-old APP/PS1-21/OR/ mice. We used 
an orexin lentiviral vector in which orexin is driven by the hypo-
cretin/orexin promoter. After injection of this vector bilaterally 
in the hypothalamus, expression of orexin in orexinergic neurons 
was restored (Fig. 5 F). 6 wk after injection with the hypocretin 
promoter–driven orexin lentiviral vector, APP/PS1-21/OR/ 
mice had a significantly increased amount of wakefulness as 
well as increased amount of A deposition in the hippocampus 
and cortex compared with mice injected with a control vector 
(Figs. 5 E and 6). Collectively, results from focal and generalized 
orexin expression in different brain regions using different pro-
moters strongly support the idea that the reduction in A pa-
thology noted in APP/PS1/OR/ mouse models is caused by 
secondary changes in sleep time induced by hypothalamic ex-
pression of orexin rather than by alteration in orexin signaling 
in hippocampus and other brain regions.
We also analyzed the functional effect of APP/PS1/OR/ 
mice in which orexin expression was rescued in orexinergic 
neurons by measuring the diurnal fluctuation of A in the 
extracellular space using in vivo microdialysis. In APP/PS1-
21/OR/ mice injected with a lentiviral vector in which 
the hypocretin/orexin promoter is driving orexin expression 
bilaterally in the hypothalamus, restoration of diurnal fluctua-
tion of ISF Ax-40 was found, suggesting possible functional 
rescue of orexinergic neurons in the hypothalamus bilaterally 
(Fig. 5, A–D). There was, however, no difference in the am-
plitude of circadian rhythms assessed by cosinor analysis be-
tween the groups (Fig. 5, C and D). This is likely caused by 
the number of mice used in this experiment.
by 11.5% during the 12-h dark phase at 3 mo of age compared 
with mice expressing orexin, before the onset of A pathol-
ogy in the brain (Fig. 1, J and K). The difference in wakeful-
ness was more prominent during the early phases of the dark 
period (6 p.m. to 12 a.m. with an 18.3% difference). Fibrillar 
A deposition assessed by X-34 staining was also markedly 
reduced in the brains of APP/PS1-21/OR/ mice and APP/ 
PS1E9/OR/ mice compared with mice expressing orexin 
(Fig. 2). We also assessed A levels biochemically. The total 
amount of both A40 and A42 solubilized by 5M guanidine 
was also significantly reduced in the hippocampus as well as 
in the cortex in APP/PS1-21/OR/ mice compared with 
APP/PS1-21 mice. Similar patterns of pathological A re-
duction were also noted in APP/PS1E9/OR/ mice com-
pared with APP/PS1E9 mice (Fig. 3).
Reversal of A pathology by modulation of sleep  
rather than focal overexpression of orexin
Orexin receptors are present on hippocampal neurons, so we 
focally overexpressed orexin by stereotaxic injection of a lenti-
viral vector expressing orexin into the hippocampus of APP/
PS1E9 mice to determine whether local orexin signaling was 
directly leading to the effects observed on A deposition. This 
treatment resulted in no changes in levels of A deposition in 
the brain nor changes in sleep time despite focal increases in the 
level of orexin in the hippocampus (Fig. 4). To further investigate 
whether the reduction in A pathology in orexin knockout 
mice is mainly caused by the effects of orexin signaling on sleep, 
expression of orexin specifically in orexinergic neurons was 
Figure 3. Strong reduction in A species in APP/PS1 mice lacking orexin. (A–D) The amount of PBS-soluble and guanidine-soluble forms of  
A40 and A42 were compared in APP/PS1E9/OR/ and APP/PS1E9 mice (left two columns) and in APP/PS1-21/OR/ and APP/PS1-21 mice (right 
two columns). Results were obtained from the hippocampus (A and B) and from the cortex (C and D) of each group of mice. Each mouse was investigated 
independently one time. All samples were measured in triplicate. Data are presented as mean ± SEM (n = 5–9 in each group, two-tailed Student’s t test).  
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decreases in sleep time and increases in amount of A levels 
and deposition have a reciprocal relationship (Kang et al., 2009; 
Roh et al., 2012; Ju et al., 2014). Intriguingly, recent results 
from humans also indicate that the quality or amount of sleep 
is inversely associated with the amount of A measured in 
the cerebrospinal fluid (CSF; Ju and Holtzman, 2013; Ooms 
et al., 2014) and that the amount of sleep inversely correlates 
with fibrillar forms of A quantified by amyloid PET scan 
(Spira et al., 2013). Treatment with active vaccination with 
A42 prevented development of A pathology and abnor-
malities of the sleep–wake cycle in APP/PS1E9 mice (Roh 
et al., 2012). This demonstrated that A aggregation and ac-
cumulation caused a sleep abnormality. In this study, the op-
posite is also true, i.e., an increase in sleep time caused by orexin 
deficiency resulted in a decrease in the amount of A pathol-
ogy that developed in the brain. Collectively, these findings sug-
gest that increasing certain types of sleep should be considered 
Sleep deprivation induced A pathology in OR/ mice
Finally, we wanted to determine whether sleep deprivation 
increased A deposition in the absence of orexin, as previ-
ously observed in the presence of orexin (Kang et al., 2009). 
We sleep-deprived APP/PS1-21/OR/ mice using the 
platform above water method as previously described (Kang 
et al., 2009). Interestingly, relative to mice that were placed 
on a large platform for 20 h per day for 3 wk, where they can 
maintain a normal sleep–wake cycle, mice placed on a small 
platform that experienced sleep deprivation had a significant 
increase in A plaque pathology (Fig. 7). Collectively, these 
findings strongly support the idea that the amount of sleep, as 
modulated by hypothalamic but not local orexin signaling, is 
crucial in regulating A metabolism and AD pathogenesis.
Increasing evidence suggests that neuronal activity in many 
brain regions is physiologically regulated by the sleep–wake 
cycle (Bero et al., 2011). It has been noted in animals that 
Figure 4. No changes in A deposition and amount of wakefulness by focal overexpression of orexin. (A–F) Amount of A pathology 
was compared after focal injection of ubiquitin-driven orexin lentiviral vector versus ubiquitin-driven GFP lentiviral vector in the hippocampus 
from 3 to 6 mo (A–C) or 5 to 9 mo (D–F) in APP/PS1E9 mice. (G) Levels of orexin in the hippocampus and CSF were compared after focal injection 
of orexin or GFP lentiviral vector driven by ubiquitin promoter. (H) The amount of wakefulness in APP/PS1E9 mice was compared after focal in-
jection of ubiquitin-driven orexin lentiviral vector versus ubiquitin-driven GFP lentiviral vector. Each mouse was investigated independently one time. 
Data are presented as mean ± SEM (n = 4–5 in each group, two-tailed Student’s t test in C, F, and H; one-way ANOVA, followed by Tukey’s post 
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proposed by Xie et al. (2013). It will be important in future 
experiments to determine whether different methods of sleep 
or orexin modulation will trigger new methods of interven-
tion targeting A pathophysiology in the brain. Given the as-
sociation between neuronal activity and release of tau in the 
brain, further studies to determine whether the sleep–wake cycle 
also influences this key molecule in the pathogenesis of AD 
and other neurodegenerative diseases will be critical (Yamada 
et al., 2014). It is important to note that other systems involved 
in the sleep–wake cycle are also likely to affect the pathophysi-
ology of AD. Even though we concluded that not orexin itself 
but rather the secondary changes in the sleep–wake cycle affect 
AD pathophysiology in brains of mice, modulation of other 
molecules that increase or decrease wakefulness such as norad-
renergic and GABAergic modulation are also likely to influence 
AD pathophysiology (Matsuki et al., 2009; Carter et. al, 2010).
The location of A deposition in the human brain overlaps 
very closely with a brain network called the “default mode” 
network, which is made up of brain regions that appear to have 
as a therapeutic target to decrease A-associated AD pathogen-
esis. Possible side effects of sleep induction such as excessive 
daytime sleepiness or cataplexy driven by knocking out or 
decreasing orexin function need to be considered in the pro-
cess of designing new therapeutic interventions targeting sleep.
It is notable that a 12% increase in the sleep time during 
the dark phase was associated with >50% reduction in the de-
velopment of A pathology in the brain. This matches well 
with the previous findings that an 15% decrease in the amount 
of soluble forms of A in the extracellular space resulted in 
an up to 50% reduction of A plaque growth and formation 
in the brain (Yan et al., 2009). It suggests that a small increase 
in NREM sleep or small improvement in sleep quality and 
the resulting decrease in A release into the extracellular space 
could be beneficial for the delay or attenuation of emergence 
of A-associated pathologies in AD. Although our data sup-
port a mechanism whereby decreased neuronal activity during 
sleep results in a decrease in ISF A, we cannot yet rule out 
the contribution of increased A clearance from the ISF as 
Figure 5. Restoration of diurnal fluctuation of ISF A40 via rescue of orexin expression in APP/PS1/OR/ mice. (A and B) Diurnal fluctuation 
of ISF A40 in young APP/PS1E9 mice was compared with the diurnal fluctuation in the same mice when orexin was knocked out (APP/PS1E9/OR/ 
mice). (C–E) Diurnal fluctuation of ISF A40 in the hippocampus and minutes awake per hour of APP/PS1-21/OR/ mice treated with hypocretin/orexin 
promoter–driven lentiviral vector overexpressing orexin in the hypothalamus bilaterally were compared with mice treated with the same lentiviral vector 
expressing GFP. (F) Expression of orexin by immunostaining in orexinergic neurons in the hypothalamus of APP/PS1-21/OR/ mice treated with hypocretin/ 
orexin promoter–driven lentiviral vector expressing GFP or orexin (middle and right) compared with wild-type mice (left). Each mouse was investigated 
independently one time. All ISF A measurements were performed in duplicate. Data are presented as mean ± SEM (n = 6 in each group, two-tailed Stu-
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For A1-x assays, a biotinylated N-terminal domain monoclonal antibody 
(3D6; Koenigsknecht-Talboo et al., 2008) followed by streptavidin– 
poly-HRP20 (Fitzgerald) was used. The antibodies m266 and 3D6 were gifts 
from Eli Lilly. All assays were developed with Super Slow ELISA TMB 
(Sigma-Aldrich) and read on a Bio-Tek Synergy 2 plate reader at 650 nm. Hip-
pocampal tissue lysates were analyzed for A1-40 and A1-42 using a denatur-
ing, sandwich ELISA specific for human A1-40 and A1-42 after solubilizing 
the tissue in 5M guanidine as previously described (Cirrito et al., 2003).
Sleep–wake monitoring. Polysomnographic sleep–wake cycle analysis of 
mice was performed as described previously (Bero et al., 2011; Roh et al., 
2012). In brief, electroencephalogram (EEG) and electromyogram (EMG) 
electrodes were implanted simultaneously with a microdialysis guide cannula. 
For EEG recording, two stainless steel screws attached to wire electrodes were 
placed over the right frontal bone (bregma +1.0 mm, 1.5 mm lateral to mid-
line) and the right parietal bone (bregma 3.0 mm, 2.5 mm lateral to midline). 
Two wire electrodes were directly inserted into the neck musculature for EMG 
recording. The ground electrode was placed on the skull over the cerebellum. 
Insulated leads from the EEG and EMG electrodes were soldered to a mini-
connector. After surgery, mice were housed in 12-h light/12-h dark for 2 wk 
before recording began. To monitor the sleep–wake cycle, we transferred the 
mice to recording cages maintained in 12-h light/12-h dark conditions (light 
phase began at 6 a.m.), and we connected the mini-connector to flexible re-
cording cables. Mice were habituated to the recording cages for 3 d. At the 
end of the habituation period, EEG and EMG recording began simultaneously 
with collection of microdialysis samples. EEG and EMG signals were dis-
played on a monitor and stored in a computer for analysis of sleep states. EEG 
and EMG recordings were assessed with a P511K AC preamplifier (Grass-
Telefactor Instruments), digitized with a DigiData 1440A Data Acquisition 
System (Molecular Devices), and recorded digitally with pCLAMP 10.2 
(Molecular Devices). EEG and EMG signals were filtered (EEG: high pass 
1 Hz, low pass 30 Hz; EMG: high pass 10 Hz, low pass 100 Hz) and used to 
the highest measures of aerobic glycolysis when individuals are 
at rest (Raichle et al., 2001; Vlassenko et al., 2010). In addition 
to the global reduction in neuronal activity resulting from an in-
crease in sleep time as shown here, focal alteration of brain 
activity, connectivity, or even focal sleep modulation through 
pharmacologic or other methods may also merit consideration 
as potential therapies in AD and other neurodegenerative dis-
orders (Nir et al., 2011; Vyazovskiy et al., 2011). Such manip-
ulation may be a powerful way to modulate A levels and 
pathology by taking advantage of normal brain physiology.
MATERIALS AND METHODS
Mice. All experiments were approved by the Animal Studies Committee 
at Washington University in St. Louis. Female APPswe/PS1E9 mice on a 
B6 background (The Jackson Laboratory) were crossed with OR/ mice on 
a C57BL/6 background to produce APPswe/PS1E9 hemizygous/OR+/ mice. 
Then, APPswe/PS1E9; OR+/ mice were crossed with OR/ mice to ob-
tain APPswe/PS1E9 hemizygous OR/ mice (APPswe/PS1E9/OR/). 
APP/PS1-21/OR/ mice were obtained using the same methods begin-
ning from crossing the APP/PS1-21 mice (C57BL/6) with OR/ mice 
(C57BL/6). APP/PS1-21 mice (C57BL/6) were provided by M. Jucker at 
the University of Tubingen (Tubingen, Germany).
ELISA. Microdialysis samples were analyzed for Ax-40, Ax-42, or A1-x 
with sandwich ELISAs. In brief, Ax-40, Ax-42, and A1-x were captured 
with monoclonal antibodies targeted against amino acids 35–40 (HJ2; Cirrito 
et al., 2003), 37–42 (HJ7.4; Roh et al., 2012), and 13–28 (m266; Cirrito et al., 
2003) of A, respectively. For Ax-40 and Ax-42 assays, a biotinylated cen-
tral domain monoclonal antibody (HJ5.1; Koenigsknecht-Talboo et al., 2008) 
followed by streptavidin–poly-HRP40 (Fitzgerald) was used for detection. 
Figure 6. Increase in A deposition and wakefulness by rescue of orexin expression in APP/PS1/OR/ mice via expression of orexin with 
lentiviral vector driven by hypocretin/orexin promoter in the bilateral hypothalamus. (A–C) Amount of A pathology in the hippocampus and 
cortex of the APP/PS1-21/OR/ mice after bilateral injection of hypocretin promoter–driven orexin lentiviral vector in the hypothalamus of the APP/PS1/
OR/ mice was compared with results from injection of the same lentiviral vector overexpressing GFP. (D) The amount of wakefulness as measured by 
polysomnography was compared between the same groups of mice. Each mouse was investigated independently one time. Data are presented as mean ± 
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for quantitative analysis of immuno- and X-34–positive staining as described 
previously (Roh et al., 2012).
Overexpression of orexin by lentiviral vector and measurement of 
orexin. Lentiviral vectors were prepared in the Hope Center Viral Vectors 
Core. For focal overexpression of orexin, orexin or GFP driven by an ubiq-
uitin promoter was overexpressed via lentivirus in the hippocampus bilater-
ally in APPswe/PS1E9 mice (B6C3) starting at 5 mo of age, and the amount 
of sleep and A pathology from both groups were compared at 9 mo. To 
investigate the effect of focal overexpression of orexin before A plaque pa-
thology was formed in the hippocampus, the same lentiviral injection exper-
iments were performed in APPswe/PS1E9 mice (B6C3) with viral injection 
at 3 mo and pathological assessment at 6 mo. For rescue of orexinergic neu-
rons, orexin or GFP driven by an hypocretin/orexin promoter was expressed 
via lentivirus in the bilateral hypothalamus in APPswe/PS1-21/Orexin 
knockout mice (C57BL/6) starting at 1.5 mo of age, and the amount of sleep 
and A pathology from both groups were compared at 3 mo. The mouse 
hypocretin/orexin promoter was provided by L. de Lecea. Brains were sec-
tioned on a freezing microtome at 50-µm thickness. Floating brain sections 
at a 1:6 series were processed for anti–orexin-A and anti–glial fibrillary acidic 
protein (GFAP) immunohistochemistry as follows: tissue was washed in Tris-
buffered saline (TBS), then quenched in 3% hydrogen peroxide solution for 
10 min, washed again in TBS, and then incubated in 0.25% Triton-X solution 
plus 5% normal goat serum for 30 min. Finally, the slides were incubated in 
primary antibody plus 5% normal goat serum, anti–orexin-A at 1:10,000 over-
night (rabbit anti–mouse Orexin-A; Phoenix Pharmaceuticals, Inc.) or anti-
GFAP at 1:1,000 (polyclonal chicken anti-GFAP; EMD Millipore). The next 
day, sections were incubated in a solution containing goat anti–rabbit IgG bio-
tinylated secondary antibody for orexin or donkey anti–chicken secondary 
identify vigilance states. EEG and EMG recordings were scored semiauto-
matically with sleep-scoring software (SleepSign; Kissei Comtec Co. Ltd.) 
and binned into 10-s epochs as wakefulness, REM sleep, and NREM sleep 
on the basis of standard criteria of rodent sleep. Semiautomatic sleep scoring 
was visually inspected and corrected when appropriate. The automatic analy-
sis and visual inspection was performed in a blinded state to the genotype and 
age of mice. Chronic sleep deprivation was performed as previously described 
(Kang et al., 2009).
Plaque deposition analyses. After mice were perfused with PBS transcar-
dially, brains were removed, fixed in 4% paraformaldehyde for 24 h (4°C), 
cryoprotected with 30% sucrose in PBS (4°C), frozen in powdered dry ice, 
and cut on a freezing sliding microtome. Serial coronal sections (50 µm thick) 
were collected from the genu of the corpus callosum to caudal hippocampus. 
Sections (each separated by 300 µm) were stained with biotinylated HJ3.4 
(A 1–13) antibody to visualize A-immunopositive plaques or X-34 dye to 
visualize fibrillar amyloid plaques (Roh et al., 2012). Immunostained sections 
and X-34–stained sections were imaged with a NanoZoomer slide scanner 
(Hamamatsu Photonics). Quantitative analysis of percent area covered by 
HJ3.4- or X-34–positive staining was performed using a neurostereological 
method as described previously (Kim et al., 2009). In brief, images of immuno-
stained sections were exported with NDP viewer software (Hamamatsu 
Photonics), converted to 8-bit grayscale with ACDSeePro 2 software (ACD 
Systems), thresholded to highlight A-specific staining, and analyzed with 
ImageJ software (National Institutes of Health). Images of X-34–stained sec-
tions were converted to 16-bit grayscale, thresholded to highlight X-34– 
specific staining, and analyzed with ImageJ software. A mouse brain atlas was used 
to identify hippocampal sections relative to bregma (1.7, 2.0, 2.3 mm) 
Figure 7. Increased A deposition with chronic sleep deprivation in APP/PS1-21/OR/ mice. (A–F) The amount of A plaques stained with 
HJ3.4B (A–C) and fibrillar A stained with X-34 (D–F) were compared between APP/PS1-21/OR/ mice exposed to a large platform and a small platform. 
Sleep deprivation experiments were performed using a small and large platform in a cage with water on the bottom, where a mouse cannot sleep on the 
small platform because of its size, whereas they can maintain a normal sleep–wake cycle on the larger platform. Mice exposed to small platforms (n = 3) 
and to large platforms (n = 3) were analyzed together within a set of experiments. The results are the sum of five repeats in different mice. Each mouse 
was investigated independently. Data are presented as mean ± SEM (n = 13–14 in each group, two-tailed Student’s t test). *, P < 0.05; and **, P < 0.01. 
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antibody for GFAP at 1:1,000 dilution, and signal was then amplified using 
the Vectastain ABC kit at 1:400 (Vector Laboratories) followed by visualization 
with DAB-nickel. Sections were carefully mounted onto glass microscope 
slides, air-dried, and then dehydrated in ascending ethanols and coverslipped 
with Cytoseal. CSF and brain tissue lysate samples were analyzed for orexin-A 
(human, rat, mouse, porcine, bovine, and ovine) levels using a commercially 
available fluorescent enzymatic immunoassay (EIA) kit (Phoenix Pharma-
ceuticals). All samples were assayed in duplicate, and the mean of the two val-
ues was reported.
In vivo microdialysis. In vivo microdialysis to assess A and lactate in the 
brain ISF of awake, freely behaving mice was performed as described previ-
ously (Cirrito et al., 2003; Roh et al., 2012). In brief, guide cannulae (BR style; 
Bioanalytical Systems) were stereotaxically implanted into hippocampus 
(bregma 3.1 mm, 2.5 mm lateral to midline, and 1.2 mm below the dura 
at a 12° angle). Probe placement in the regions of interest was confirmed 
by cresyl violet staining. Microdialysis probes (2 mm; 38-kD molecular size 
cutoff; BR style; Bioanalytical Systems) were connected to a syringe pump 
(Stoelting Co.), and artificial CSF, pH 7.35, containing 1.3 mM CaCl2, 1.2 mM 
MgSO4, 3 mM KCl, 0.4 mM KH2PO4, 25 mM NaHCO3, and 122 mM 
NaCl was continuously perfused through the microdialysis probe. For mea-
surement of Ax-40, a flow rate of 0.5 µl/min was used. Guide cannulae were 
implanted 2 wk before the beginning of microdialysis. After insertion of the mi-
crodialysis probe, mice were habituated to a 12-h light/dark cycle for three 
more days. On the fourth day, samples were collected and stored for analyses.
Statistical analysis. Statistical significance was determined by two-tailed 
Student’s t test if the datasets fulfilled the normality test (Kolmogorov–Smirnov 
test). When the dataset did not meet the assumptions of a parametric test, 
Mann–Whitney rank sum test was performed. One-way ANOVA followed 
by Tukey’s post hoc test for multiple comparisons was performed if the datasets 
fulfilled the equal variance test (Levene’s test) and normality test (Kolmogorov–
Smirnov test). All statistical analyses were performed with Prism version 4.0 
for Windows (GraphPad Software) and SPSS 15.0 for Windows (SPSS Inc.). 
Values were accepted as significant if P < 0.05.
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